Neuroendovascular Coil Market (2025 - 2030)

Neuroendovascular Coil Market Size & Trends

The global neuroendovascular coil market size was estimated at USD 1.04 billion in 2024 and is projected to grow at a CAGR of 6.5% from 2025 to 2030. This growth is attributed to the increasing incidence of cerebral aneurysms and strokes, fueled by aging populations and lifestyle-related risk factors such as hypertension, smoking, and diabetes.

Technological advancements have significantly enhanced procedural efficacy and safety, including developing next-generation detachable, hydrogel-coated, and 3D complex coils. According to the data by NIH 2025, each year, an estimated 795,000 people in the U.S. experience a stroke, with approximately 610,000 of these being first-time occurrences. Nearly one in four stroke survivors will suffer a subsequent stroke. Among all stroke cases, about 87% are classified as ischemic strokes, while the remaining 13% are hemorrhagic strokes.

The aging population significantly drives the neuroendovascular coil market due to the higher prevalence of neurological conditions, such as aneurysms, which are more common in older adults. As the elderly population grows, the demand for minimally invasive treatments, such as neuroendovascular coil embolization, increases, as these procedures are safer and involve quicker recovery than traditional surgery. Additionally, the higher risk of complications in older patients, such as aneurysms bursting or strokes, further boosts the demand for neuroendovascular coils. Healthcare systems worldwide are adapting to the needs of aging populations, increasing treatment resources, and creating favorable reimbursement policies, which helps expand the market. Moreover, the focus on improving the quality of life for elderly individuals enhances the demand for advanced, minimally invasive options such as neuroendovascular coils, contributing to the market's growth.

The below graph presents projected data on the proportion of the population aged 65 and older across various OECD countries by the year 2050, highlighting the global trend of population aging. Countries such as South Korea (39.8%), Japan (37.7%), and Italy (33.7%) are expected to have the highest percentages of elderly individuals, indicating rapid demographic shifts driven by increased life expectancy and declining birth rates. Additionally, it indicates a growing demand for age-related medical interventions and technologies, such as neuroendovascular coils, as the incidence of conditions such as stroke is expected to rise with the aging demographic.

Hypertension is one of the most significant risk factors for a variety of vascular diseases, including cerebral aneurysms, strokes, and other cerebrovascular abnormalities. Its growing prevalence globally is a critical factor driving the expansion of the neuroendovascular coil market. Neuroendovascular coils are widely used in the treatment of brain aneurysms and vascular malformations, which are caused or exacerbated by uncontrolled hypertension. Hypertension is the leading cause of hemorrhagic strokes. It contributes to the narrowing and hardening of arteries, making them more susceptible to blockage or rupture. Neuroendovascular procedures, including the use of coils, are a frontline treatment for hemorrhagic strokes caused by ruptured aneurysms. The increasing global burden of hypertension, especially in low- and middle-income countries where blood pressure control is insufficient, is expected to lead to a rise in stroke cases, thereby propelling the demand for neuroendovascular interventions. According to the British Heart Foundation BHF, 2025, it is estimated that around 30% of UK adults, approximately 16 million people, are living with high blood pressure, and up to half of them are not receiving effective treatment. While about 11 million individuals have been diagnosed by their general practitioner, this suggests that up to 5 million adults may remain undiagnosed. In total, up to 8 million people in the UK could be living with undiagnosed or uncontrolled high blood pressure.

Aneurysms in the brain, which occur when blood vessels weaken and form a bulge, are a significant concern among the aging population. The risk of aneurysms increases with age, particularly after age 50. As the number of elderly individuals rises globally, the occurrence of aneurysms has become more prevalent, fueling demand for treatment options. Neuroendovascular coils are one of the preferred methods for treating these aneurysms, as they involve less invasive techniques than traditional surgery, making them more suitable for elderly patients who may have other health concerns or are not candidates for more invasive procedures.

According to the Brain Aneurysm Foundation 2024,

• Approximately 6.8 million people in the U.S. have an unruptured brain aneurysm 1 in 50 people.

• The annual rupture rate is around 8-10 per 100,000 people.

• About 30,000 people in the United States suffer a brain aneurysm rupture each year one rupture every 18 minutes.

• Nearly 500,000 deaths worldwide are caused by brain aneurysms annually.

• Half of the cases of brain aneurysms are younger than 50.

Market Concentration & Characteristics

The market growth stage is high, and the pace of growth is accelerating. Modern neuroendovascular coils are made from biocompatible and shape-memory alloys, such as platinum, nitinol, or combinations that offer better flexibility, visibility under fluoroscopy, and thrombogenic properties. Coils are also being developed with hydrogel coatings that expand upon contact with blood, filling aneurysms more completely and reducing recurrence rates. Traditional helical coils have evolved into complex three-dimensional (3D) shapes, such as framing, filling, and finishing coils, which improve packing density and conform more closely to the aneurysm sac.

The level of mergers and acquisitions activity in the neuroendovascular coil market has been moderate, reflecting the market's growth potential, technological complexity, and increasing strategic interest from large medical device companies. Several factors drive this trend, including the need for portfolio expansion, technological integration, global market access, and consolidation in a competitive landscape. Leading neurovascular companies have been actively acquiring smaller, innovation-driven firms to strengthen their neuroendovascular portfolios. For instance, in May 2023, Stryker completed its acquisition of Cerus Endovascular Ltd., a privately held medical device company specializing in neurointerventional devices for treating intracranial aneurysms. Cerus Endovascular's CE-marked products, including the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, are expected to expand Stryker's portfolio of aneurysm treatment solutions. These devices address the growing need for one-and-done intrasaccular aneurysm therapy.

Regulations significantly impact the neuroendovascular coil market, influencing product development, approval, commercialization, and post-market surveillance. Stringent regulatory requirements, particularly in the U.S. and Europe, affect the time and cost of launching new products to market. In the U.S., the FDA’s approval processes, such as the 510(k) and Premarket Approval (PMA), require strict clinical testing and substantial evidence of safety and efficacy. Similarly, the European Union’s Medical Device Regulation (EU MDR) has introduced more stringent rules than its predecessor, demanding extensive clinical evaluation, risk assessment, and documentation. While essential for ensuring patient safety and device reliability, these regulations can pose significant barriers to entry, especially for small and medium-sized enterprises.

Product expansion drives growth and competitiveness in the neuroendovascular coil market. As the demand for minimally invasive treatments for brain aneurysms and other neurovascular conditions rises, manufacturers expand their product portfolios to offer more advanced, effective, and tailored solutions for various clinical scenarios. Product expansion involves the development of next-generation coil technologies, such as hydrogel-coated coils, bioactive coils, and complex 3D-shaped coils, which provide better aneurysm filling, promote healing, and reduce the risk of recurrence. Companies are also innovating in coil delivery systems, improving precision, control, and flexibility for neurointerventional working in delicate cerebral vessels.

Regional expansion is a key growth strategy in the neuroendovascular coil market, as manufacturers seek to tap into emerging markets and strengthen their presence in established regions. With the rising global burden of neurological disorders, particularly brain aneurysms and strokes, expanding into new geographic areas enables companies to access larger patient populations, diversify revenue streams, and reduce dependency on saturated markets.

Type Insights

Bare platinum coils dominate the market due to their long-established clinical efficacy and widespread adoption. As the first generation of neuroendovascular coils, they have a proven track record in treating cerebral aneurysms and other neurovascular conditions. These coils are highly effective for small aneurysms with simple geometries, offering reliable occlusion and preventing rupture. Bare platinum coils are also cost-effective, making them accessible in developed and resource-limited settings, where affordability is crucial. Their compatibility with standard neurointerventional equipment, such as catheters and microcatheters, ensures their broad use across hospitals, surgery centers, and clinics. Moreover, bare platinum coils have received extensive regulatory approvals from the FDA and CE and are trusted by clinicians worldwide. The long-term clinical data supporting their safety and efficacy further solidifies their position as the preferred choice for many neurointerventional procedures, particularly in treating simple aneurysms and follow-up treatments.

The hydrogel-coated coils segment is expected to experience the fastest CAGR in the market due to their innovative design and significant clinical advantages over traditional bare platinum coils. Hydrogel-coated coils are enhanced with a hydrophilic coating that increases their volume and stability once deployed inside an aneurysm, providing a more effective occlusion and reducing the risk of recanalization. Their ability to create a stronger and more durable thrombus and achieve better volumetric filling of aneurysms drives their growing adoption, particularly in regions where advanced neuro interventions are becoming more common. Additionally, these coils are designed to reduce procedural complications, such as coil migration or coil compaction, leading to improved patient outcomes and faster recovery times, enhancing their appeal to healthcare providers and patients.

Application Insights

The cerebral aneurysm application segment dominates the market due to the high global prevalence of aneurysms and the established clinical efficacy of coiling as a first-line treatment, particularly for unruptured and ruptured aneurysms. A cerebral aneurysm is a localized dilation of a cerebral artery wall, which can rupture and cause subarachnoid hemorrhage, a life-threatening form of stroke. Neuroendovascular coiling has become the standard of care for many of these aneurysms because it is minimally invasive, has a lower procedural risk compared to surgical clipping, and is associated with shorter recovery times and improved neurological outcomes. Moreover, cerebral aneurysms account for the majority of procedures performed using neuroendovascular coils, making them the dominant application by volume and revenue. Aging populations, mainly in developed regions, contribute significantly to this trend, as aneurysm incidence increases with age. Additionally, increasing awareness, patient screening programs, and public health initiatives focused on stroke prevention are expected to further boost procedure rates.

The cerebral infarction segment is expected to grow at a significant CAGR in the market, primarily driven by the rising global burden of ischemic strokes, technological advancements in interventional devices, and evolving treatment protocols that expand the use of coiling and adjunctive neurovascular therapies. Cerebral infarction, commonly known as ischemic stroke, occurs when a blood vessel supplying the brain becomes obstructed due to a clot. While mechanical thrombectomy using stent retrievers and aspiration catheters remains the primary approach for large vessel occlusions, coiling and embolization techniques are being employed for stroke-related complications such as pseudoaneurysms, arteriovenous fistulas, or hemorrhagic transformation following infarction.

End Use Insights

The hospital segment dominates the market due to its advanced infrastructure, specialized personnel, and comprehensive emergency care capabilities. Hospitals are the primary centers equipped with advanced neurointerventional suites, biplane imaging systems, and intensive care units required for complex procedures such as intracranial aneurysm coiling, arteriovenous malformation embolization, and treatment of acute ischemic strokes. These facilities support 24/7 emergency interventions crucial for hemorrhagic stroke management and attract referrals from smaller clinics and regional centers. The presence of trained interventional neuroradiologists, neurosurgeons, and neurologists enables hospitals to handle a wider variety of cases, including complex or ruptured aneurysms that require multidisciplinary expertise.

The ambulatory surgery centers (ASCs) segment is expected to grow at the fastest CAGR, driven by healthcare system shifts toward cost-efficiency, patient convenience, and technological miniaturization. ASCs offer a streamlined, outpatient-focused care model that enables faster turnaround times, reduced hospitalization costs, and lower infection risks than traditional hospitals. With the advancement of minimally invasive neurointerventional techniques and the development of softer, more navigable coils, many less complex cerebral aneurysms can be treated safely in ASC settings. In addition, the adoption of portable imaging systems and compact catheterization labs has expanded the capabilities of ASCs to handle neurovascular procedures that were once confined to tertiary hospitals.

Regional Insights

North America neuroendovascular coil market dominated the global market with a revenue share of 36.71% in 2024, driven by its advanced healthcare infrastructure, high disease awareness, strong presence of leading medical device companies, and robust regulatory frameworks. The region’s dominance is underpinned by several key factors contributing to its leadership in innovation and adoption of neurointerventional technologies. North America benefits from a comprehensive network of hospitals, stroke centers, and specialized neurovascular units equipped with advanced diagnostic and interventional technologies. These facilities can perform complex procedures such as coil embolization, often with access to the latest generation devices.

U.S. Neuroendovascular Coil Market Trends

The U.S. held the largest share in North America neuroendovascular coil market in 2024.The increasing incidence of cerebral aneurysms and strokes is one of the primary drivers of the neuroendovascular coil market in the United States. This trend creates a growing clinical need for effective, minimally invasive treatments, directly impacting demand for coil embolization procedures. According to the National Institutes of Health, in the U.S., cerebrovascular disorders, which include conditions like stroke, affect around 800,000 people annually, making stroke the fifth leading cause of death.

Clinical trials significantly drive the neuroendovascular coil market by generating strong clinical evidence that validates the safety, efficacy, and long-term outcomes of coil systems used to treat cerebral aneurysms and other neurovascular conditions. Moreover, clinical trials are essential for obtaining regulatory approvals from the FDA, providing the data required to support product clearance or approval. They also allow manufacturers to highlight innovative features, such as bioactive, hydrogel-coated, or stretch-resistant coils, that improve clinical performance and patient outcomes. By differentiating products in a competitive market, trials help drive brand-specific demand. Additionally, clinical trial data are crucial in shaping reimbursement decisions by demonstrating cost-effectiveness and improved healthcare outcomes, encouraging insurance providers to cover these procedures. As a result, clinical trials validate current technologies and accelerate the adoption of newer coil systems, expand treatment indications, and ultimately stimulate market growth.

Below table shows some major clinical trials in neuroendovascular coil market in the U.S.

Source: ClinicalTrials.gov

Europe Neuroendovascular Coil Market Trends

Europe neuroendovascular coil market held a substantial market share in 2024. Europe faces a significant burden of cerebrovascular conditions such as intracranial aneurysms, subarachnoid hemorrhage, and ischemic strokes. According to the European Stroke Organisation (ESO), stroke is the second leading cause of death in Europe, with over 1 million deaths annually. The incidence of unruptured intracranial aneurysms, discovered during imaging for other conditions, is also rising. As the population continues to age and risk factors like hypertension, obesity, and smoking remain prevalent, the clinical demand for neuroendovascular interventions, including coiling, has grown significantly.

The Stroke Action Plan for Europe (SAP-E), launched in 2018, is a collaborative initiative led by the ESO and Stroke Alliance for Europe (SAFE). It provides a comprehensive roadmap for improving stroke care across Europe by 2030. The plan addresses prevention, treatment, rehabilitation, and long-term care, with a strong focus on reducing the burden of stroke and enhancing the quality of life for stroke survivors. This plan shapes future healthcare investments, neurointerventional services, and market opportunities, including for neuroendovascular devices such as coils.

"Stroke can be prevented and treated due to the significant discoveries over recent decades. However, there is still a significant gap between knowledge and the delivery of stroke services despite the high cost-effectiveness of stroke care. All stroke patients across Europe should have access to the best possible evidence-based care to ensure the best quality of life post stroke. Implementing the Stroke Action Plan for Europe will help us achieve this."- Professor of Neurology and Chair of the Stroke Action Plan for Europe

The neuroendovascular coil market in the UK is expected to grow significantly in the forecast period. The UK is witnessing an increase in the number of patients diagnosed with intracranial aneurysms and ischemic strokes, particularly among older adults. According to the Stroke Association UK, over 100,000 strokes occur annually, and approximately 1.3 million people are living with the effects of a stroke. As unruptured aneurysms are diagnosed through imaging, more patients are being considered for preventive embolization with coils, boosting demand. As per the NHS, around 1 in 15,000 people have a ruptured brain aneurysm in England each year. The UK’s National Health Service has invested heavily in building a nationwide stroke care network, including specialist stroke units, hyperacute stroke centers, and mechanical thrombectomy services. Many of these centers are equipped to perform neuroendovascular procedures, including coil embolization for aneurysms. NHS England’s Long-Term Plan includes expanding access to neurointerventional and thrombectomy, supporting market growth. ​

The Germany neuroendovascular coil market is growing. Germany has a significant burden of neurovascular diseases, particularly among the aging population. According to the NIH, stroke remains a leading cause of disability and death in Germany. The proportion of individuals aged 65 and above is steadily increasing. This demographic is more susceptible to aneurysms and stroke, boosting the demand for neuroendovascular therapies like coiling. German institutions such as the Center for Neurovascular Diseases Tübingen and the Germans Trias i Pujol Research Institute (IGTP) are actively engaged in neurovascular research and multi-center clinical trials, accelerating the introduction and acceptance of new neuroendovascular devices. The country has a strong network of neurosurgeons and interventional neuroradiologists skilled in using neuroendovascular coils, which supports the market’s growth. The proportion of individuals aged 65 and above is increasing. This demographic is more susceptible to aneurysms and stroke, directly boosting the demand for neuroendovascular therapies like coiling. According to EUROSTAT, the proportion of the population aged 65 and over was 22.40% in December 2024.

Asia Pacific Neuroendovascular Coil Market Trends

The Asia-Pacific neuroendovascular coil market is witnessing the fastest growth globally due to demographic, epidemiological, technological, and healthcare infrastructure developments. A rapidly aging population across countries such as Japan, China, and South Korea has led to a higher incidence of neurovascular disorders such as cerebral aneurysms and strokes, which are key indications for endovascular coiling. Additionally, the increasing prevalence of risk factors such as hypertension, diabetes, and sedentary lifestyles has contributed to a surge in demand for neurointerventional procedures. Improved access to advanced diagnostic tools like MRI, CT, and digital subtraction angiography (DSA) has enabled earlier detection of aneurysms and arteriovenous malformations, leading to preventive coiling interventions. According to the Journal of Asian Pacific Society of Cardiology. The overall prevalence of hypertension in the Asia-Pacific region ranged between 10.6% and 48.3%. Furthermore, investments in healthcare infrastructure, particularly in emerging economies such as India and China, have expanded the availability of specialized neurosurgical and endovascular services. The region also benefits from rising awareness among patients and healthcare professionals regarding the advantages of minimally invasive neurointerventional techniques, which offer quicker recovery and reduced post-operative complications compared to traditional surgery.

The neuroendovascular coil market in India is anticipated to witness the significant growth in the Asia Pacific market over the forecast periodIndia's growing burden of cerebrovascular diseases is one of the most significant factors driving demand for neuroendovascular coils. Stroke is the second leading cause of death and a significant cause of long-term disability in India, with ischemic and hemorrhagic strokes becoming common. In India, the burden of stroke is substantial and growing, with profound implications for the healthcare system and public health. Stroke ranks as the fourth leading cause of death and the fifth leading cause of disability in the country. The incidence of stroke in India ranges from 119 to 145 per 100,000 population annually, with a higher prevalence observed in urban areas compared to rural regions. The rising prevalence of risk factors such as hypertension, diabetes, obesity, smoking, and sedentary lifestyles, particularly among younger populations, is accelerating the incidence of brain aneurysms and other neurovascular conditions. This epidemiological trend is creating an urgent need for minimally invasive, effective treatment options like coil embolization. According to government of India, as of March 2025, a total of 42.01 million individuals have received treatment for hypertension, while 25.27 million have been treated for diabetes.

China neuroendovascular coil market is growing. Driven by the rising incidence of neurovascular diseases, mainly due to the country’s aging population and increasing prevalence of risk factors such as hypertension, diabetes, and smoking. China faces one of the highest stroke burdens globally, with millions of new cases annually, fueling demand for effective neurointerventional treatments such as coil embolization. Furthermore, advancements in coil technology, such as developing hydrogel-coated and bioactive coils, are improving treatment efficacy and expanding the scope of conditions that can be managed endovascularly. These innovations are complemented by improved procedural tools, such as adjunctive stents and microcatheters, which enhance precision and outcomes. The expansion of neurointerventional capabilities across China has also played a key role. Tertiary hospitals are being upgraded, and specialized stroke centers are proliferating, allowing for more widespread access to complex procedures. Additionally, government-supported training programs have significantly increased the number of skilled neuro interventionists. The Chinese government’s ongoing healthcare reforms, under initiatives like “Healthy China 2030,” are further supporting the adoption of advanced medical technologies.

Middle East and Africa Neuroendovascular Coil Market Trends

The Middle East and Africa (MEA) neuroendovascular coil market is experiencing significant growth, due to increase in the prevalence of stroke, brain aneurysms, and arteriovenous malformations, fueled by aging populations, urbanization, and lifestyle-related risk factors such as hypertension, smoking, obesity, and diabetes. These trends create a growing demand for advanced neurointerventional procedures, including the use of neuroendovascular coils for aneurysm embolization. Governments in the Gulf Cooperation Council (GCC) countries, such as Saudi Arabia, the UAE, and Qatar, are making significant investments in healthcare modernization. New hospitals and specialized centers are being established, with enhanced access to neurosurgery and interventional neuroradiology services. These developments support the adoption of advanced devices such as neuroendovascular coils.

Key Neuroendovascular Coil Company Insights

Some key companies operating in the market includeStryker, Balt, Johnson & Johnson, Boston Scientific Corporation, Medtronic, and TERUMO CORPORATION. Strategic initiatives involve mergers, acquisitions, and collaborations to broaden product offerings and market presence, alongside focused research and development to improve product efficacy and utilize innovative technologies.

Recent Developments

• In January 2025, Kaneka Corporation, a Tokyo-based healthcare company, announced the acquisition of a 96.8% stake in EndoStream Medical Ltd., an Israeli medical device startup headquartered in Or Akiva. Kaneka's broader strategy is to expand its healthcare business and strengthen its position in the neurovascular treatment market.

• In May 2023,CERENOVUS, Inc., a part of Johnson & Johnson MedTech, has announced the U.S. commercial launch of its latest neurovascular innovation, the CEREPAK Detachable Coils, and confirmed that the first patient cases have been successfully performed.

• In December 2022, Stryker has received FDA 510(k) clearance for its Target Tetra Detachable Coil — a next-generation neuroendovascular coil designed to treat small cerebral aneurysms.

Neuroendovascular Coil Market